News Hub | News Direct

Modivcare Launches Non-Emergency Medical Transportation Provider Academy to Champion Success and Engagement

Modivcare

Modivcare Inc. (“Modivcare”) (Nasdaq: MODV), a technology-enabled healthcare services company that provides a suite of integrated supportive care solutions focused on improving patient outcomes, today announced the launch of Modivcare Academy. The innovative program supports transportation providers who own, work for, or operate non-emergency medical transportation (NEMT) companies by providing education, networking opportunities, and training resources. “The introduction of Modivcare Academy is an extension of our purpose, to ensure greater access to care by serving the needs of our communities,” said Daniel Greenleaf, President and CEO of Modivcare. “Our unique program, offered to emerging NEMT companies that contract with us, supports the ongoing business success of transportation providers who are a driving force for positive change within their communities.” Modivcare Academy empowers drivers with information and insights about the latest innovative technology, provides industry best-practices training, and offers resources to support running an NEMT business. The program was kicked-off in Chicago at the December 2021 inaugural Modivcare Academy event that featured subject matter experts offering insights about strategic growth, marketing and sales, customer engagement, operations, financial management, and technology adoption. “We are strongly committed to investing in the success of transportation providers because they serve a critical role in breaking down the barriers that stand in the way of access to care,” added Greenleaf. “Our transportation providers represent a broad and diverse pool of businesses, including disadvantaged, small, minority, and women-owned firms who are committed to providing safe and reliable transportation to the patients we jointly serve. We were overwhelmed by the positive response to our Chicago event and look forward to hosting future events in other communities in 2022.” “As transportation providers, we have faced many COVID-19 challenges, but we have stayed focused and have overcome these hurdles by concentrating on our patients,” said Brisa Berumen-Dixon, a transportation provider with Seabreeze NEMT, Rockford, Illinois. “The most rewarding part of what we do is improving the quality of life for individuals within our hometown communities, which is made possible through our relationship with Modivcare.” To further improve the driver experience and support their business success, Modivcare also launched a “Voice of the Customer” survey program to collect real-time feedback and a Transportation Advisory Council to support the needs of transportation providers. Modivcare’s non-emergency medical transportation services provide access to safe, reliable rides to health services. Working with local, community-based transportation providers, Modivcare is the largest broker of NEMT in the nation and brings more than 35 years of experience to its more than 6,500 transportation providers and provides more than 75 million trips annually to 30 million patients across the nation. Modivcare Academy empowers drivers with information and insights about the latest innovative technology, provides industry best-practices training, and offers resources to support running an NEMT business. The program was kicked-off in Chicago at the December 2021 inaugural Modivcare Academy event that featured subject matter experts offering insights about strategic growth, marketing and sales, customer engagement, operations, financial management, and technology adoption. # # # # About Modivcare Modivcare Inc. (“Modivcare”) (Nasdaq: MODV) is a technology-enabled healthcare services company that provides a suite of integrated supportive care solutions for public and private payors and their patients. Our value-based solutions address the social determinants of health (SDoH), enable greater access to care, reduce costs, and improve outcomes. We are a leading provider of non-emergency medical transportation (NEMT), personal and home care, remote patient monitoring, medication management and nutritional meal delivery. Modivcare also holds a minority equity interest in CCHN Group Holdings, Inc. and its subsidiaries (“Matrix Medical Network”), which partners with leading health plans and providers nationally, delivering a broad array of assessment and care management services to individuals that improve health outcomes and health plan financial performance. To learn more about Modivcare, please visit www.modivcare.com. Contact Details Kate Zerone Senior Manager, Communications kate.zerone@modivcare.com Kim Warth Amendola Communications kwarth@acmarketingpr.com

February 22, 2022 09:30 AM Eastern Standard Time

Image

Brush Up on Oral Health: Technology For Your Mouth Leading To Healthy, Confident Smiles

YourUpdateTV

A video accompanying this announcement is available at: https://youtu.be/UIgoM06hR04 How do you get that ‘fresh from the dentist’ clean feeling on the 360+ days you’re not at the dentist? You turn to a revolutionary kit that integrates advanced technology to deliver brighter, whiter smiles and cleaner, healthier teeth. The result is that consumers look and feel their best and enjoy greater confidence as they go about their day. Built by dental professionals, izzoTM was developed by fourth-generation family-owned Premier Dental, a global developer and manufacturer of dental and medical products that has been in business for 100+ years, with a presence in 76 countries. Julie Charlestein, the President and CEO of Premier Dental, conducted a nationwide media tour to discuss the launch of izzo TM, an innovative new direct to consumer initiative designed to elevate at-home oral care. While brushing your teeth regularly is certainly important, izzo TM is the first and only 4-in-1 oral care system that goes significantly beyond just the typical toothbrush to give your teeth a whole new level of clean. izzo is technology for your mouth leading to healthy, confident smiles. izzo not only helps you brush effectively, it helps you polish to remove surface stains for a brighter, whiter smile; scale to remove plaque and debris between teeth; and sanitize your brush to ensure it’s germ-free for your next use. Best of all, it gives you that ‘fresh from the dentist’ clean feeling and a healthy confidence to look and feel your best. The revolutionary izzo system is currently available online for purchase at www.izzosmile.com for $129.95. For more information or to read first-hand product reviews, please visit www.izzosmile.com. About izzo TM izzo TM is the revolutionary 4-in-1 home oral care system that helps consumers look and feel their best through healthier, whiter smiles. izzo includes a toothbrush, polishing system (polisher & enamel polishing paste), scaler and sanitizer. Made in partnership with Premier ® Dental Products Company, a 4th generation, family-run business established in 1913, izzo reflects the knowledge of over 100 years in developing professional-grade oral care products. This differentiated product introduces innovative in-home dental care directly to consumers through an easy-to-use kit and a convenient Subscribe & Save program. For more information, please visit www.izzosmile.com. About Premier Dental ® Products Company Premier Dental ® is a global privately-held business dedicated to delivering inspired solutions for daily dentistry. Dental professionals have turned to Premier for over 100 years as a leader in bringing innovative products to market that improve their daily procedures, practices and patient outcomes. Contact Details YourUpdateTV +1 212-736-2727 yourupdatetv@gmail.com

February 18, 2022 01:54 PM Eastern Standard Time

Video

Quotient Sciences Completes Integration Of Drug Substance Into Translational Pharmaceutics® Platform

Quotient Sciences

Quotient Sciences – a global drug development and manufacturing accelerator offering a suite of services to clients in the pharmaceutical and biotech industry – announces that it has integrated drug substance into its flagship Translational Pharmaceutics ® platform. The newly integrated service unites drug substance, drug product and clinical testing activities all within a unified organization and under a single project manager. The full integration of drug substance R&D and manufacturing follows a year after the company’s acquisition of its Alnwick, UK site and provides a more streamlined approach from candidate selection through to commercialization. Quotient Sciences Translational Pharmaceutics ® approach – combining manufacturing and clinical dosing at a single organization – enables innovators to adjust formulations and dosing in real time. “Our Translational Pharmaceutics ® platform is now in its 15 th year and has accelerated development timelines for more than 500 drug programs. We remain the only outsourcing partner able to offer innovators the ability to manufacture, release, and dose under one organization. This approach is proven to shave 12-months of timelines and, by adding drug substance synthesis, the timeline from candidate selection to clinic can be a further accelerated by 2-4 months,” commented Mark Egerton, CEO of Quotient Sciences. Translational Pharmaceutics ® was developed in consultation with the MHRA & FDA and employs a rapid “make-test” cycle, where drug products are manufactured, released, and dosed in a clinical study in days rather than months. This means biotechs and pharma companies can fast track molecules from First in Human (FIH) through Proof of Concept (POC). “By fully integrating drug substance with drug product and clinical testing activities, Quotient Sciences can closely align manufacturing and dosing workflows, greatly improving R&D efficiencies, and increasing the potential for clinical and commercial success,” stated Peter Scholes, CSO of Quotient Sciences. “In fact, an independent study by the Tufts Center of the Study of Drug Development (CSDD) showed Translational Pharmaceutics delivered $200milllion in drug development cost saving per approved drug.” “Our purpose has always been to bring new medicines to patients faster, and our new capabilities in drug substance continue to break down traditional industry silos. As we look to the future, Quotient will continue to bring on new services that further integrate drug development and streamline the outsourcing needs of our customers,” added Egerton. [1] https://www.quotientsciences.com/news/tufts-csdd-demonstrates-multi-million-dollar-benef/ About Quotient Sciences Quotient Sciences is a drug development and manufacturing accelerator providing integrated programs and tailored services across the entire development pathway. Cutting through silos across a range of drug development capabilities, we save precious time and money in getting drugs to patients. Everything we do for our customers is driven by an unswerving belief that ideas need to become solutions, and molecules need to become cures, fast. Because humanity needs solutions, fast. For more information visit quotientsciences.com. Contact Details De Facto Communications Abdul Khalifeh +44 20 3735 8165 a.khalifeh@defacto.co.uk Company Website https://www.quotientsciences.com/

February 17, 2022 09:12 AM Eastern Standard Time

Image

VinFuture foundation officially launches the call for 2022 VinFuture Prize nominations

Vingroup

HANOI, VIETNAM - Media OutReach - 17 February 2022 - The VinFuture Prize has officially opened the nomination portal for the second season from February 16th until May 17th, 2022. The 2022 season of VinFuture Prize is looking for scientific inventions and innovations that can help revive the world and build up sustainable development after the pandemic. The Laureates of the VinFuture Grand Prize 2021 Following the success of the inaugural VinFuture Prize with 4 honored breakthroughs in science and technology that can positively impact humanity on a global scale – The second season of the Prize has been launched and welcomed by the international community of science. The focus of the VinFuture Prize’s second season is to honor outstanding scientific innovations that can help reimagine post-pandemic life and stimulate sustainable development. This reflects VinFuture’s consistent vision and mission of “Science for humanity”. If health protection was the challenge of mankind in 2021, “Reshaping and Reviving” is the imperative that the world needs to cope with in 2022. Centering around the theme of “Reshaping and Reviving”, the second season of the VinFuture Prize hopes to motivate and inspire scientists around the world. Through the Prizes, VinFuture wishes to support people to overcome topical post-pandemic challenges and create positive changes for millions of human lives on earth this year. Commenting on the outstanding nominations of 2021 and looking forward to this year’s submissions, Prof. Sir Richard Henry Friend – Chair of the VinFuture Prize Council, said: “Last year’s prize awards celebrate very clearly how science and innovation can bring real global benefits for health. However, humankind faces big challenges in many other areas, including natural resource consumption, the move to zero carbon to avoid damaging climate change, and others. This year we want to reach as widely as we can, across disciplines and across continents, to broaden the scope and impact of the VinFuture Prizes in reviving the post-pandemic world.” To be eligible for participating in the VinFuture Prize 2022, the applications are required to meet the nomination criteria* and be nominated by reputable organizations/individuals in the field of science and technology around the world. Nominations will be evaluated in the pre-screening and selection stages by the Pre-screening Committee and the VinFuture Prize Council respectively. Members of the Prize Council and Pre-screening Committee are top global scientists, inventors and laureates of the Nobel Prize, Turing Award, Millenium Technology Prize, and other global awards. Sharing about the expectations for the call for nominations of the second VinFuture Prize season, Prof. Văn-Chí Đặng, Scientific Director of Ludwig Cancer Research Institute (USA) and a member of the VinFuture Prize Council, said: “Science and technology is the answer to the challenges and urgent global problems that people are facing. In order to have more inventions that help change people’s lives regardless of origin, skin color, or ethnicity, for this year’s Prize, we expect to receive more exceptional scientific solutions, in more diverse fields, across more geographical areas, and from scientists regardless of age, gender, or nationality,… with the potential for application on a larger scale." The inaugural VinFuture Prize received tremendous support from the global scientific and technological community, with 599 quality nominations from scientists, researchers, and innovators from six continents. The VinFuture Grand Prize, valued at US$ 3 million, was awarded to a group of three scientists: Dr. Katalin Karikó (USA), Prof. Drew Weissman (USA), and Prof. Pieter Cullis (Canada) for the development of mRNA technology, paving the way for the production of effective vaccines to help prevent COVID-19 outbreaks. The VinFuture Special Prize for Innovators with Outstanding Achievements in Emerging Fields was awarded to Prof. Omar Yaghi (USA) for his pioneering work on the discovery and development of metal-organic framework materials (MOFs). The VinFuture Special Prize for Female Innovators was awarded to Prof. Zhenan Bao (USA) for the scientific advancements from her pioneering work on developing skin-inspired organic electronics materials. The VinFuture Special Prize for Innovators from Developing countries was granted to two scientists from South Africa, Prof. Salim Abdool Karim and Prof. Quarraisha Abdool Karim, whose research helps prevent HIV transmission and lessen the burden of the AIDS epidemic. 2022 online nomination portal: https://online.vinfutureprize.org/nomination For more information about the Prize: Detailed instructions on the nomination process and the Nomination Form: https://online.vinfutureprize.org/nomination FAQs: https://vinfutureprize.org/faqs/ The first-year VinFuture Prize Laureates were announced at the Award Ceremony on January 20th, 2022. Information about the awarded innovations can be found here: https://vinfutureprize.org/laureates/ *The ten major nomination criteria of the VinFuture Prize are: There should be clear evidence, or potential, for an end-product or service based on the solution, which has an everyday practical application; Solutions should have already benefited millions of people in the past 10 years for the Grand Prize, or have the potential to benefit millions of people in the next 10 years for the Special Prizes; Solutions should be aligned with one or more of the United Nation’s SDGs; Solutions must be scientifically proven (i.e., there should be clear evidence of passing relevant scientific trials, and in the case of research, it must be empirically proven or widely reviewed); Open to researchers or inventors who were involved in developing the underlying solutions, and not entrepreneurs or corporates who helped in the commercialization/diffusion of the technology; End-products of the research should benefit people globally, including those from developing and less developed countries, as well as lower-income and disadvantaged communities; Open to individuals or teams of researchers/inventors; Preferences are considered for nominees in the active stages of their careers; A nominator can only nominate one nominee/one group of nominees for each of the four Prize categories. Research/Solution/Invention can be underpinned in any discipline of science, engineering, or technology, including potentially multi-disciplinary approaches. About VinFuture Foundation: The VinFuture Foundation, established on December 20th, 2020 on the occasion of International Human Solidarity Day, is an independent, not-for-profit foundation initiated by Mr. Phạm Nhật Vượng, the Chairman of Vingroup JSC, Vietnam’s leading private conglomerate, and his wife, Mrs. Phạm Thu Hương. The Foundation was established to honor and facilitate breakthrough scientific research and technological innovations that have already contributed or have the potential to contribute to the betterment of life for millions of human beings globally while creating a more sustainable world for future generations. The VinFuture Prize consists of four prize categories, of which the Grand Prize – with a value of US$3 million – is one of the largest annual global prizes, and three additional Special Prizes, worth US$500,000 each, are dedicated to Female Innovator(s), Innovator(s) from Developing Country(ies), and Innovator(s) with Outstanding Achievements in Emerging Fields. In addition, the Foundation also conducts many activities to realize its mission, such as funding research, collaborating in academic development, and promoting STEM education. Contact Details Vingroup Media Contact v.nammh@vingroup.net Company Website https://online.vinfutureprize.org/nomination/s/welcome

February 17, 2022 08:30 AM Eastern Standard Time

Image

G Medical Innovations Announces that More than 200,000 LiveNow At-Home COVID-19 PCR Tests are Now Available at 4,000+ Circle K Locations Nationally, with 300,000 More to Ship in the Coming Weeks

G Medical Innovations Holdings

G Medical Innovations Holdings Ltd. (NASDAQ: GMVD) announced today that more than 200,000 of its LiveNow COVID-19 PCR collection kit tests are now available at more than 4,000 Circle K convenience stores nationally. Another 300,000 kits will ship to the retailer within the next few weeks. The kits are expected to generate approximately $12 million in revenue, based on the expected return of at least 100,000 kit samples to the company’s testing lab. Circle K is one of the largest independent convenience store operators in the United States. “As a result of our highly successful partnership with McDade Products for brand development and national retail distribution, millions more of the LiveNow PCR Collection Kits are in production. They will continue to ship to Circle K stores and will fulfill significant orders for kits from other national retailers to be announced soon”, said Dr. Yacov Geva, President and CEO of G Medical Innovations. In response to a national shortage of COVID-19 test options, Pittsburgh-based McDade Products, LLC and G Medical Tests and Services, a division of G Medical Innovations, partnered in January to make several million COVID-19 PCR collection kit tests available for retailers. G Medical Innovations is a telehealth, medical device, and remote patient monitoring company providing clinical-grade solutions for consumers, medical professionals, and healthcare institutions. McDade Products is a division of McDade Group, a specialty sales, marketing, and distribution company serving the U.S. retail industry. The LiveNow diagnostic PCR (polymerase chain reaction) test detects the presence or absence of SARS-CoV2, the virus that causes COVID-19. The PCR test type, which requires approved lab certification, has been widely recognized as more accurate because it is more sensitive than antigen tests. Visit https://www.mcdadegrp.com/ to place orders for the LiveNow PCR Collection Kits. About McDade Group Founded in 1994, McDade Group is a growing and dynamic sales, marketing, and distribution services company headquartered in Pittsburgh, PA. The company has expanded to provide solutions in distribution, category management, full-service merchandising, and consulting across the U.S. retail industry. Many of the world’s leading CPG manufacturers rely on the ability of McDade Group to build strong industry relationships and deliver services, insights, and expertise for hundreds of their products. Visit: https://www.mcdadegrp.com/ or LinkedIn: https://www.linkedin.com/company/mcdade-group/. About G Medical Innovations G Medical Innovations Holdings Ltd. is an early commercial-stage healthcare company engaged in the development of next-generation mHealth and telemedicine solutions and monitoring service platforms. The Company’s solutions and services can empower consumers, patients, and providers to better monitor, manage and improve clinical and personal health outcomes, especially for those who suffer from cardiovascular disease (or CVD), pulmonary disease, and diabetes. The Company’s current product lines consist of its Prizma medical device, a clinical-grade device that can transform almost any smartphone into a medical monitoring device, enabling both healthcare providers and individuals to monitor, manage and share a wide range of vital signs and biometric indicators; its Extended Holter Patch System, a multi-channel patient-worn biosensor that captures electrocardiography (or ECG) data continuously, including its QT Prolongation Syndrome Detection Capabilities Patch. In addition, the Company is developing its Wireless Vital Signs Monitoring System (or VSMS), which is expected to provide full, continuous, and real-time monitoring of a wide range of vital signs and biometrics. Its monitoring services include provision of Independent Diagnostic Testing Facility (or IDTF) monitoring services and private monitoring services. Visit https://gmedinnovations.com/. Forward-Looking Statements This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995 and other Federal securities laws. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates,” and similar expressions or variations of such words are intended to identify forward-looking statements. For example, G Medical is using forward-looking statements when it discusses delivery of purchase orders, anticipated revenue, production of additional LiveNow PCR Collection Kits, that it will continue to ship to Circle K stores and will fulfill significant orders for kits from other national retailers to be announced soon. Because such statements deal with future events and are based on G Medical’s and McDade Products’ current expectations, they are subject to various risks and uncertainties, and actual results, performance, or achievements of G Medical and McDade Products could differ materially from those described in or implied by the statements in this press release. The forward-looking statements contained or implied in this press release are subject to other risks and uncertainties, including those discussed under the heading “Risk Factors” in G Medical’s prospectus filed pursuant to Rule 424(b)(4), filed with the Securities and Exchange Commission (“SEC”) on June 28, 2021, the registration statement on Form F-1 filed on February 14, 2022 (registration no. 333-262724) and in any subsequent filings with the SEC. Except as otherwise required by law, the companies undertake no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. G Medical and McDade Products are not responsible for the contents of third-party websites. Contact Details G Medical Innovations Kobi Ben-Efraim, CFO +972 8-958-4777 service@gmedinnovations.com Company Website https://gmedinnovations.com/

February 16, 2022 07:00 AM Eastern Standard Time

CURE Token Launches CURE Chain Development by Securing Technical Advisor Jim Nasr

CURE Token, LLC

Jacob Beckley, visionary founder of CURE Token and THE BECKLEY FOUNDATION philanthropist, has set his sights on another new and exciting venture in his quest to upend traditional approaches to medical research and to enable universal access to medical care, especially for the underserved. As COVID hampered the The Beckley Foundation's fundraising events and efforts, Beckley needed innovative, alternative ways to fund its commitments to active medical research programs. CURE Token was launched to fill funding gap, and instead exploded in a short time to a $52M market cap, enabling the expansion of the Beckley foundation's mission to include supplementing the devastating patient and family costs associated with childhood cancer care. "Supporting childhood cancer research, patients and their families is a compassionate effort, and I'm pleased we are able to make even a small difference", says Beckley, "but it's the tip of an iceberg fraught with underlying problems in an industry disinterested in change". He goes on to describe two fundamental healthcare industry problems at opposite ends of the delivery system. "Researchers need to share data, every day, real-time, in an anonymous, secure system. COVID vaccines are an example of the speed and acuity that can be brought to bear through real-time collaboration. That same process needs to be replicated every day, in every way, on every research project. By the time professional papers are published and peer reviewed, it's already old news". At the other end of the spectrum Beckley talks about his primary goal: patient access. "All the medical research, innovation and development in the world is worthless if patients are unable to access it due to economics or geography. Healthcare access should not be limited to the wealthy, the insured, or the geographically well located. Healing is for everyone." CURE Chain, Beckley's visionary concept to address both of these goals is becoming a reality, and he's harnessing the horsepower to make it happen sooner rather than later. Jim Nasr, a well-respected tech innovator and CEO of Acoer, an award-winning tech firm specializing in user friendly blockchain development will join Beckley in structuring and launching CURE Chain. Nasr is well versed in the healthcare industry, from his role as chief software architect for the Centers for Disease Control (CDC) in the US, his collaboration with Mayo Clinic's development of their connected diagnostics platform, and positions on a variety of key healthcare technology committees and related boards. https://images.squarespace-cdn.com/content/v1/5af858de1aef1df75ada4dce/4a886ac6-bbde-4bf9-8a2e-d191eabccf97/cure-chain-leadership.png?format=1000w "CURE Chain provides a novel opportunity to address the issues that Jacob has identified. As example, through use of Non-Fungible Tokens (NFTs) on a public Distributed Ledger Technology (DLT) network, we intend to reference clinical research and patient data uniquely, securely and in a privacy preserving manner. This DLT “anchoring” will significantly increase confidence on the authenticity of the underlying data and accountable monitoring and usage it," says Nasr. “We firmly believe that properly conceived DLT and blockchain integration as an underlayer of computational trust can lead to decentralized healthcare delivery and the leveling of the playing field—reducing the gap between the developed and underdeveloped health systems, the insured and uninsured, and the wealthy and the poor." Full CURE Chain implementation will proceed after the conclusion of the already underway key design activities. These include: Technical architecture design—on schedule, with the technical team already hard at work, identification of research organizations for piloting clinical trial data exchange, and the development of patient user experience models. "Financial institutions tried to thwart cryptocurrency development and growth, but it happened anyway by mass demand. CURE Chain will change a healthcare industry that doesn't know it's broken and has no motivation to change, and it will do it by mass demand," Beckley explains. "Once it catches on and people, both researchers and patients, see the value change will be monumental". A pretty bold, futuristic statement, but it comes from someone whose title is "Senior Vice President of Innovation, Product and Technology" at one of the country's acclaimed digital innovation firms, Fusion92. Perhaps it's time to pay attention. Contact Details Eric Brown +44 7960 044904 eric@curetoken.net

February 15, 2022 10:00 AM Eastern Standard Time

Image

QX Global Group Acquires Management Consulting & Advisory Services Firm Chazey Partners

QX Global Group

Together QX Global Group and Chazey Partners will provide end-to-end Business Transformation, Digital Services & Intelligent Automation, and Business Process Outsourcing (BPO) for Fortune 1000 companies and public sector organizations, including higher education, across the globe. QX Global Group, a Top 100 Business Process Outsourcing company, announced the acquisition of an 80% stake in Austin, Texas-based Chazey Partners, a world-class management consulting and advisory firm specializing in business and digital transformation. The Chazey Partners team brings decades of experience in implementing and operating world-class business support and shared services organizations around the globe, with expertise in Robotic Process Automation (RPA) and Artificial Intelligence (AI). Together, QX and Chazey Partners will work to deliver innovative solutions that cover transformative consulting, digital services, and business process outsourcing, customized to meet each client’s specific needs. “At QX, we have always focused on enabling transformation of our client’s businesses using our unique 3P approach of people, process, and platform, and we are thrilled that the addition of Chazey will allow us to help organizations solve their most significant barrier to growth – digital adoption and business transformation at scale, said Frank Robinson, Group CEO of QX Global Group. “Adding Chazey furthers our vision to provide integrated, end-to-end solutions to help our customers take advantage of the latest operating models and emerging technologies. I am also delighted to officially welcome Phil Searle onto QX Global Group’s Board as Chief Transformation Officer.” Chazey brings to the QX Global Group management consulting and advisory services with a global reach. Founded in 2006, Chazey Partners has demonstrated consistent and significant growth, with global representation in the United States, Canada, Mexico, Brazil, Costa Rica, Colombia, Ireland, Turkey, and India. Chazey’s consultants provide advice, support, and implementation expertise, covering strategy setting, business case production, program management, process optimization, technology enablement, training, and change management. “ Since founding the company, we have significantly expanded and evolved Chazey’s solutions to help numerous businesses and public sector organizations achieve operational excellence by transforming their business operations,’’ said Phil Searle, CEO and Founder of Chazey Partners. ‘’With QX, we have found a shared passion for empowering our clients to achieve world-class performance. By joining forces with QX, we will augment our near-shoring and offshoring capabilities by opening new Centers of Excellence (COEs) in India and Latin America. This is an exciting new chapter for Chazey Partners, our employees, and our customers.” The partnership of both trusted brands comes at a time when enterprises across the globe are adjusting to the post-pandemic world. In this environment, Chazey Partners is at the forefront of offering needed transformation solutions, helping enterprises optimize business operations and adopt the latest technologies for sustained growth. The QX-Chazey partnership will enable all clients to achieve a faster return on investment and add more value to their customers and employees. Barbara Hodge, Global Digital Editor at the Shared Services & Outsourcing Network (SSON), said, “This marks an exciting and timely development in the shared services and outsourcing space. SSON has collaborated with Chazey Partners for many years, and I am pleased to see such a highly respected group in the field of business transformation push forwards in extending its services to provide enterprise customers with the more holistic solutions they need right now. Adding Chazey Partners’ transformation capabilities to QX Global Groups’ BPO services, drives an end-to-end solution that connects consulting, digital and business process outsourcing. This aligns perfectly with the move to integrated business services, digitalization – driven by intelligent automation – and data analytics, that we are seeing across the shared services landscape. It’s also consistent with service providers moving to a ‘one-stop-shop’ solution for business transformation and digital needs. I am delighted at this news and look forward to engaging with the new partnership.” For QX Global Group: Corbett Keeling, London, and J. Sloan & Co, Dallas, Texas, provided corporate finance and transaction advice for QX Global Group; BDO LLP provided Due Diligence support across all entity geographies; legal support was provided by Munsch Hardt Kopf & Harr, P.C. For Chazey Partners: Sett & Lucas acted as transaction advisor, and Jackson Walker LLP provided legal support. About QX Global Group QX Global Group is a leading provider of business process management services. With over 17 years of accounting and recruitment process outsourcing experience, we help our clients unlock business value by improving process efficiencies and automation in the accounting and recruitment functions to enable business transformation. We have offices in the UK, USA, Canada, Australia, and India. About Chazey Partners Chazey Partners is a practitioner-led, global management consulting and advisory services firm. We bring real-life, practical, hands-on experience, empowering clients to strive for world-class performance, through Business Transformation, Shared Services, and Intelligent Automation. We help businesses and public sector organizations achieve operational excellence in the provision of mission-critical business services, including Finance, Human Resources, IT, Procurement, Contact Centers, Marketing, and Facilities Management. For over sixteen years, Chazey Partners has helped clients implement successful service delivery solutions; in the US & Canada, Latin America, Europe, the Middle East, Africa, Oceania, and Asia. Contact Details QX Global Group Vishal Kurani +44 20 8146 0808 vishal.kurani@qxglobalgroup.com Chazey Partners Leigh Knowles +1 855-692-6229 LeighKnowles@chazeypartners.com Company Website https://qxglobalgroup.com/

February 14, 2022 09:55 AM Eastern Standard Time

Six talented women climate scientists from developing countries awarded the 2022 OWSD-Elsevier Foundation Award

Elsevier

Six researchers have been awarded the 2022 OWSD-Elsevier Foundation Award for Early-Career Women Scientists in the Developing World for their contributions to research that is helping tackle climate change and advancing the UN Sustainable Development Goals (SDGs) including: SDG13 (Climate Action), SDG14 (Life Below Water) and SDG15 (Life on Land). The winners’ research explores a wide range of environmental impacts and their potential solutions: from turning waste into man-made soil; transforming plastic pollution into viable products for community trade; harnessing the power of microbes to improve carbon storage and soil quality; and using the right types of plants with roots to help prevent soil erosion and encourage soil ‘plasticity’. The prize also acknowledges the scientists’ commitment to leadership, mentoring and engagement within their communities, including the use of innovative technologies in their research. President, Jennifer Thomson, of the Organization for Women in Science for the Developing World (OWSD) said: “What our 2022 winners are doing is absolutely outstanding. Climate change is the most pressing challenge of our time, and these women are finding innovative and effective ways to address it in their local contexts. We hope this award is the first of many for them.” This year’s winners are: Myriam Mujawamariya of the University of Rwanda; in Biological Systems and Organisms. Abeer Ahmed Qaed Ahmed of Al-Saeed University, Yemen; in Biological Systems and Organisms. Gawsia Wahidunnessa Chowdhury of the University of Dhaka, Bangladesh; in Biological Systems and Organisms. Heyddy Calderon of the Instituto de Geología y Geofísica, Nicaragua; in Engineering Sciences Ashani Ssavinda Ranathunga of University of Moratuwa, Sri Lanka; in Engineering Sciences. Flor de Mayo Gonzalez Miranda of San Carlos University, Guatemala; in Engineering Sciences. Those interested can meet the winners for the first time, as they appear virtually in the upcoming panel, “ Minority and Women in STEMM Awards,” at the upcoming AAAS Annual Meeting. First awarded in 2013, the award is given in partnership by the OWSD and Elsevier Foundation. OWSD chairs a panel of distinguished scientists to select the winners, and the Foundation awards a cash prize for each winner of USD $5,000, as well as an all-expenses-paid trip to attend a prominent scientific gathering to provide them with vital networking opportunities. This year’s award ceremony will take place on March 24, both virtually and in-person as part of the International Conference on Gender Action and Climate Change in Istanbul, Turkey at Istanbul Aydin University (IAU) on March 24, 2022. Ylann Schemm, Director of the Elsevier Foundation said: “We have reshaped our award this year to respond to the key challenges of our time, such as climate change, and supporting the progress being made around the UN SDGs. We know that a quarter of all women are engaged in agriculture, which makes them more vulnerable to both climate change and resource scarcity. We want to reflect the critical role that women can play in successfully addressing climate shifts.” Past Award winners have been invited to meet their country’s presidents, and have been celebrated by local, national and international media, while other winners have gone on to receive other prestigious awards and fellowships including L'OREAL-UNESCO’s For Women in Science Fellowships and the British Council Award. Read more about this year’s OWSD-Elsevier Foundation Award on Elsevier Connect. --- Notes for editors Reference sheets for each award winner, with a more extensive biography and description of their work, are available upon request, please contact the Elsevier Newsroom at newsroom@elsevier.com. For interview requests, journalists can contact Domiziana Francescon, Elsevier Foundation & External Partnerships Manager at d.francescon@elsevier.com. Short bios of the 2022 winners: Myriam Mujawamariya in Biological Systems and Organisms. For her research on the responses of native tree species in Rwanda to climate change. Her work will inform the most effective approach to reforestation and land restoration and identify the best tree species to facilitate soil stabilization, climate regulation, biodiversity, and bioenergy. ''Receiving this prestigious award is a great recognition and driving force to expand my research. This is also an inspiration for young girls in advancement of their career to ensure equity in Climate action and the Environment in the developing world,” said Dr. Mujawamariya Abeer Ahmed Qaed Ahmed in Biological Systems and Organisms. For her work on microbiology- and nanotechnology-based solutions to pressing problems such as carbon emissions, drug-resistant pathogens, and fossil fuel dependence. She has studied the use of microbes in agricultural land to increase carbon sequestration and improve soil quality, the use of microbes to convert biomass into pharmaceuticals, and the effects of environmental and nutritional conditions on microbial biological processes to inform treatment against multi-drug resistant microorganisms. “The OWSD-Elsevier Foundation Award gave me encouragement and recognition during an important time on my journey as a scientist. This recognition will inspire me to keep going and inspire young people who are looking up to us to light their paths. This award gave me confidence and showed me that I am going in the right direction,” said Dr. Ahmed. Gawsia Wahidunnessa Chowdhury in Biological Systems and Organisms. For her work on conservation of aquatic ecosystems and threatened species in Bangladesh. In particular, she focuses on assessing the extent of and the risks from plastic pollution, which is closely linked to climate change. Dr. Chowdhury is leading an effort to educate women in poor and marginalized fishing communities about how discarded Nylon-6 fishing nets can be turned into value-added products such as carpets and clothing, creating an alternative income source for the communities while protecting the wetland habitats. “Winning this Award is like a promise to continue my research and teaching with new hope. This award gives me a scope to prove what women in science and conservation can achieve while working hard with sincere commitment. I believe this award will inspire my daughter, my students and everyone here in Bangladesh to showcase that with different limitations, scientific research can be done and achieved recognition worldwide,” said Dr. Chowdhury. Heyddy Calderon in Engineering Sciences. For her work to provide secure and sustainable water sources for vulnerable populations in Central America. Dr. Calderon works with local communities in dry regions to increase their capacity to cope with climate variability and climate change, as well as with decision makers and local stakeholders to help them plan and prepare for the future. “This award is an inspiration to me. I am joyful and honored by the recognition of my work; but also, I feel the responsibility to keep pushing boundaries for the women who come behind us,” said Dr. Calderon. Ashani Ssavinda Ranathunga in Engineering Sciences. For her work turning industrial and agricultural waste into anthropogenic (man-made) soil for soft ground improvement and mine rehabilitation. Her research findings enable the effective utilization of locally available waste and by-products for economical and ecofriendly construction and development projects. “This award recognizes my contribution to the field of geo-environmental engineering and encourages me to follow my passion and inspire young women in developing countries to take the initiative to work for the advancement of science, irrespective of their circumstances,” said Dr. Ranathunga. Flor de Mayo Gonzalez Miranda in Engineering Sciences. For her work engineering better landslide prevention for vulnerable areas in Guatemala. Dr. González Miranda is investigating how specific grasses in the vetiver can help to prevent landslides. Through soil tests, X-ray diffraction, and other techniques, she has shown how the plants' roots alter the chemical, physical and mechanical behavior of the soil, reducing the speed of soil infiltration as well as soil plasticity. “This award allows me to say that all living organisms are a system that must follow its natural evolution. It also gives me back my voice to tell politicians that corruption takes away human development and pushes the great masses to emigrate, expressing my urgency to legislate on measures to protect the environment: that these laws are not dead words,” said Dr. Gonzalez Miranda. To find out how the OWSD-Elsevier Foundation Award helps shape our understanding of the Global South, find out more about 2021’s winners below: Harnessing nanotechnology for cancer drug delivery and ecofriendly fertilizers How my teacher said I asked too many questions: From curious to award winning researcher Using mathematics to solve practical problems: It's elementary Seeking the secrets of the universe in the particle Ghanaian chemist is finding toxic substances in unusual places About OWSD The Organization for Women in Science for the Developing World (OWSD) provides research training, career development and networking opportunities for women scientists throughout the developing world. Headed by eminent women scientists from the South, OWSD has more than 7,000 members and runs various programs, including a PhD fellowship programme with over 330 successful graduates from Least Developed Countries and sub-Saharan Africa, as well as an Early Career fellowship programme providing research grants of up to USD$50,000 in addition to leadership training. OWSD is the first international forum to unite women scientists from the developing world with the objective of strengthening their role in the development process and promoting their representation in scientific and technological leadership. OWSD is affiliated with The World Academy of Science (TWAS), a program unit of UNESCO, and is based in Trieste, Italy, with national chapters throughout the developing world. www.owsd.net About The Elsevier Foundation The Elsevier Foundation is a corporate not-for-profit 501(c)(3), funded by Elsevier, a global information analytics business specialized in science and health. Since 2006, the Elsevier Foundation provides over $1.5 million USD a year in grants to knowledge-centered institutions around the world, which address the UN Sustainable Development Goals through tech-enabled innovations in inclusive health and research. The Foundation offers a comprehensive matching gift and volunteering fund to enable employees to work with Foundation partners and support their communities. The Elsevier Foundation is part of Elsevier’s larger corporate responsibility program which centers on our unique contributions to sustainable development in gender, health, climate and reducing inequalities. elsevierfoundation.org About Elsevier As a global leader in information and analytics, Elsevier helps researchers and healthcare professionals advance science and improve health outcomes for the benefit of society. We do this by facilitating insights and critical decision-making for customers across the global research and health ecosystems. In everything we publish, we uphold the highest standards of quality and integrity. We bring that same rigor to our information analytics solutions for researchers, health professionals, institutions and funders. Elsevier employs 8,100 people worldwide. We have supported the work of our research and health partners for more than 140 years. Growing from our roots in publishing, we offer knowledge and valuable analytics that help our users make breakthroughs and drive societal progress. Digital solutions such as ScienceDirect, Scopus, SciVal, ClinicalKey and Sherpath support strategic research management, R&D performance, clinical decision support, and health education. Researchers and healthcare professionals rely on our 2,500+ digitized journals, including The Lancet and Cell; our 40,000 eBook titles; and our iconic reference works, such as Gray's Anatomy. With the Elsevier Foundation and our external Inclusion & Diversity Advisory Board, we work in partnership with diverse stakeholders to advance inclusion and diversity in science, research and healthcare in developing countries and around the world. Elsevier is part of RELX, a global provider of information-based analytics and decision tools for professional and business customers. www.elsevier.com Contact Details Erin Johnson OWSD Communications ejohnson@owsd.net Jonathan Davis j.davis.1@elsevier.com Elsevier Communications, Europe newsroom@elsevier.com Company Website https://www.elsevier.com/

February 11, 2022 09:05 AM Eastern Standard Time

Regenerative Medicine Company Vascudyne Relocates to High Capacity GMP Manufacturing Facility

Vascudyne, Inc.

Vascudyne, Inc., a biotechnology trailblazer in regenerative medicine, announced today that it has relocated to 15,000 sq. ft. of recently remodeled manufacturing, warehouse, laboratory, and office space. This new facility is needed to meet increased demand for research and development and manufacturing of Vascudyne’s TRUE™ Tissue technology that is unique and 100% natural. Nothing synthetic or artificial is ever used in the manufacturing process, in contrast to other regenerative medicine cardiovascular devices with synthetic polymer-based scaffolds that slowly degrade in the body and may lead to adverse immune response. Vascudyne announced in July the successful first human use of its TRUE™ Graft for hemodialysis access in end-stage renal disease patients. “The addition of a dedicated 5,000 sq. ft. ISO 7 Cleanroom manufacturing facility is paramount for the successful continuation of our TRUE Graft clinical studies,” said Cory Pries, Director of Quality at Vascudyne. “The expandable manufacturing capacity we have added is designed to support our current pilot clinical studies all the way to initial commercialization.” "We are dedicating 2,500 sq. ft. of the ISO 7 Cleanroom space to our new product development pipeline for coronary artery bypass graft, heart valves, and surgical patches," added Dr. Zeeshan Syedain, Vascudyne’s Chief Scientific Officer. “While we are initially focusing on cardiovascular applications for our TRUE Tissue technology, we can readily manufacture products and delivery systems for a range of medical devices, implantation sites, and geometries. We are excited to develop implantable biomaterials that are ready to use, off-the-shelf, and regenerative.” Vascudyne announced in December the closing of its Series A financing round for $10M that has fueled its growth and enabled the company’s relocation to the new facility. “Our investors’ continued support and promising early results from TRUE Graft’s first in man pilot study have propelled our growth,” said Rick Murphy, Vascudyne’s Chief Operating Officer. “We are establishing a strong presence in the epicenter of the Medical Alley, the Silicon Valley of Healthcare, and are creating excellent employment opportunities for talented people in the area. The move to this new facility positions us well to meet growing global demand for our products.” Vascudyne licensed its proprietary TRUE Tissue technology developed by world renowned tissue engineering leader Robert Tranquillo, PhD, Distinguished McKnight University Professor, and his colleagues from the University of Minnesota in 2017. TRUE Graft is not available for commercial sale. About Vascudyne Headquartered in the heart of Medical Alley in Minnesota, Vascudyne is on a mission to improve patient care with regenerative biomaterials that are inspired by nature. Vascudyne, a privately held company founded in 2014, uses the TRUE™ Tissue technology to develop TRUE to Nature™ biomaterials for soft tissue repair and replacement. For more information, please visit https://www.vascudyne.com/. About TRUE Tissue Technology TRUE™ Tissue is developed from cells isolated from donor tissue and is 100% biological. There are no synthetic materials or chemical fixation used, and implanted tissues are completely cell-derived and acellular. The TRUE Tissue technology can be readily shaped into tubes, sheets, and other geometries making it suitable for many soft tissue applications, is mechanically comparable to native tissues, and is a ready to use, off-the-shelf allograft. Forward Looking Statements This announcement contains forward-looking statements. Such statements may include, without limitation, statements identified by words such as "projects," "may," "will," "could," "would," "should," "believes," "expects," "anticipates," "estimates," "intends," "plans," "potential" or similar expressions. These statements relate to future events or Vascudyne’s clinical development programs, reflect management’s current beliefs and expectations and involve known and unknown risks, uncertainties and other factors that may cause Vascudyne’s actual results, performance or achievements to be materially different. Vascudyne undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future presentations or otherwise, except as required by applicable law. Contact Details Sandy Williams, Marketing Director swilliams@vascudyne.com Company Website https://vascudyne.com/

February 09, 2022 09:23 AM Eastern Standard Time

Image